Category: Today’s Highlights

ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results

ImmunoGen in the NEWS Immunogen ( IMGN ) - a developer of  antibody-drug conjugates ( ADCs ) for cancer treatment , today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2023. From...

Read More

November 2, 2023

0

Amylyx Pharma Informed European CHMP is Trending Toward a Negative Opinion for Conditional Marketing Authorization of AMX0035 for ALS

Amylyx Pharmaceuticals  Amylyx Pharmaceuticals ( AMLX ) announced an update on the ongoing review of its Marketing Authorization Application ( MAA ) for AMX0035 (taurursodiol]) regarding the treatment of adults with amyotrophic lateral sclerosis ( ALS ) by the Committee...

Read More

May 30, 2023

0

Sanofi to Acquire Translate Bio, Advancing mRNA Technology. See Also: Cassava Science Q2 Financial Results

Sanofi Will Acquire Translate Bio Sanofi ( SNY ) will acquire all the outstanding shares of  Translate Bio ( TBIO )  for $38.00 per share in cash, which represents a total equity value of approximately $3.2 billion (on a fully diluted basis). The Sanofi and...

Read More

August 3, 2021

0

Why the UT Southwestern Medical Center is Enrolling Cancer Patients in Phase III TIGeR-PaC Clinical Trial from RenovoRx

UT Southwestern Medical Center and RenovoRx RenovoRx Inc ( RNXT ) announced that the University of Texas ( UT ) Southwestern Medical Center is now enrolling pancreatic cancer patients in the open label, randomized Phase III TIGeR-PaC clinical trial. The...

Read More

June 1, 2023

0

CRISPR Therapeutics Announces Preclinical Data at the American Heart Association Scientific Sessions 2023

CRISPR Therapeutics Data Presentation Announcement CRISPR Therapeutics ( CRSP ) today announced preclinical data from the Company’s investigational programs for the treatment of cardiovascular disease at the American Heart Association ( AHA ) Scientific Sessions 2023. The data will be...

Read More

November 6, 2023

0

Arbutus Biopharma Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial That Includes a PD-1 Monoclonal Antibody Nivolumab

Arbutus Biopharma Announcement Today, June 21, 2023, Arbutus Biopharma ( ABUS ) announced that the first patient has been dosed in the additional treatment arm of the AB-729 Phase 2a triple combination clinical trial, which has been expanded to include...

Read More

June 21, 2023

0

AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in Netherlands to Start Phase 1b/2 Study Evaluating Ampligen in Combination with AstraZeneca Imfinzi for Treatment of Pancreatic Cancer

AIM ImmunoTech Announcement AIM ImmunoTech ( AIM ) - an immuno-pharma company focused on the research and development of its TLR-3 agonist Ampligen (rintatolimod) as a novel and potentially powerful therapeutic in locally advanced pancreatic cancer ( “LAPC” ) and...

Read More

June 27, 2023

0

Agenus Inc Corporate Update and Financial Results for Q2 2021. See Also: Why Intellia Was Down Today

Agenus Inc News and Q2 Results for 201 Agenus ( AGEN ) announced results with better than usual news including the following:  $200 million received from BMS for anti-TIGIT bispecific antibody collaboration FDA cleared IND for AGEN1777 clinical enrollment AGEN1181...

Read More

August 9, 2021

0

Vertex Pharmaceuticals and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY

Vertex Pharmaceuticals and CRISPR Therapeutics Announce Authorization of CASGEVY Conditional Approval for Both Sickle Cell Disease and Transfusion Dependent Beta Thalassemia Vertex Pharmaceuticals ( VRTX ) and CRISPR Therapeutics ( CRSP ) today announced that the United Kingdom (U.K.) Medicines...

Read More

November 16, 2023

0

Anavex Announced US Patent Office Granted a Patent No. 11,813.242 Entitled A273 a Therapeutic for Insomnia, Anxiety and Agitation

Anavex Life Sciences Granted US Patent Anavex Life Sciences ( AVXL ) – a development-stage biopharmaceutical company announced that the United States Patent and Trademark Office ( USPTO ) granted U.S. Patent No. 11,813,242 entitled “A273 as a therapeutic for insomnia, anxiety, and agitation.  This patent expands Anavex’s existing patent coverage of ANAVEX®273 (blarcamesine), including U.S. Patent No. 11,337,953 to cover Anavex’s leading drug candidate, ANAVEX®2-73, and NANVEX®14141...

Read More

November 22, 2023

0

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0